Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GMED NYSE:HAE NASDAQ:IRTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMEDGlobus Medical$86.41-3.1%$90.00$51.79▼$101.40$11.70B11.20 million shs1.15 million shsHAEHaemonetics$56.15+6.6%$59.68$47.31▼$87.32$2.61B0.53817,573 shs846,558 shsIRTCiRhythm Technologies$124.67+5.9%$121.80$112.31▼$212.00$4.09B1.33630,079 shs423,526 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMEDGlobus Medical-0.74%+1.72%+0.72%+2.08%+26.61%HAEHaemonetics-5.60%-10.97%-10.03%-19.20%-17.47%IRTCiRhythm Technologies-0.35%-2.53%+0.41%-19.80%-12.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMEDGlobus Medical$86.41-3.1%$90.00$51.79▼$101.40$11.70B11.20 million shs1.15 million shsHAEHaemonetics$56.15+6.6%$59.68$47.31▼$87.32$2.61B0.53817,573 shs846,558 shsIRTCiRhythm Technologies$124.67+5.9%$121.80$112.31▼$212.00$4.09B1.33630,079 shs423,526 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMEDGlobus Medical-0.74%+1.72%+0.72%+2.08%+26.61%HAEHaemonetics-5.60%-10.97%-10.03%-19.20%-17.47%IRTCiRhythm Technologies-0.35%-2.53%+0.41%-19.80%-12.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMEDGlobus Medical 2.88Moderate Buy$104.3620.78% UpsideHAEHaemonetics 2.73Moderate Buy$82.7847.42% UpsideIRTCiRhythm Technologies 2.93Moderate Buy$193.3855.11% UpsideCurrent Analyst Ratings BreakdownLatest GMED, HAE, and IRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026IRTCiRhythm Technologies CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$155.00 ➝ $157.005/1/2026IRTCiRhythm Technologies Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$198.00 ➝ $180.005/1/2026IRTCiRhythm Technologies JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$215.00 ➝ $175.005/1/2026IRTCiRhythm Technologies Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$200.00 ➝ $180.005/1/2026IRTCiRhythm Technologies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$254.00 ➝ $255.004/21/2026IRTCiRhythm Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026GMEDGlobus Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/15/2026IRTCiRhythm Technologies Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$200.00 ➝ $170.004/13/2026HAEHaemonetics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$80.00 ➝ $70.004/9/2026IRTCiRhythm Technologies The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$184.00 ➝ $147.003/18/2026GMEDGlobus Medical Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMEDGlobus Medical$2.94B3.98$6.03 per share14.33$33.86 per share2.55HAEHaemonetics$1.32B1.98$7.27 per share7.72$16.34 per share3.44IRTCiRhythm Technologies$747.14M5.48N/AN/A$4.91 per share25.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMEDGlobus Medical$537.87M$3.9421.9617.712.1018.30%12.57%10.87%5/7/2026 (Estimated)HAEHaemonetics$167.68M$3.6315.4510.631.0913.31%27.32%9.61%5/7/2026 (Estimated)IRTCiRhythm Technologies-$44.55M-$0.86N/A95.17N/A-3.53%-10.26%-1.39%N/ALatest GMED, HAE, and IRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026GMEDGlobus Medical$0.92N/AN/AN/A$740.35 millionN/A5/7/2026Q4 2026HAEHaemonetics$1.28$1.29+$0.01-$0.44$336.83 millionN/A4/30/2026Q1 2026IRTCiRhythm Technologies-$0.56-$0.35+$0.21-$0.43$194.11 million$199.39 million2/24/2026Q4 2025GMEDGlobus Medical$1.06$1.28+$0.22$1.03$803.29 million$826.42 million2/19/2026Q4 2025IRTCiRhythm Technologies$0.02$0.29+$0.27$0.17$202.61 million$208.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGMEDGlobus MedicalN/AN/AN/AN/AN/AHAEHaemoneticsN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMEDGlobus MedicalN/A4.262.74HAEHaemonetics1.011.751.15IRTCiRhythm Technologies4.035.174.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMEDGlobus Medical95.16%HAEHaemonetics99.67%IRTCiRhythm TechnologiesN/AInsider OwnershipCompanyInsider OwnershipGMEDGlobus Medical18.38%HAEHaemonetics1.84%IRTCiRhythm Technologies0.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMEDGlobus Medical6,000135.25 million110.39 millionOptionableHAEHaemonetics3,02346.47 million45.62 millionOptionableIRTCiRhythm Technologies2,40032.86 million32.54 millionOptionableGMED, HAE, and IRTC HeadlinesRecent News About These CompaniesWall Street Analysts Predict a 57.21% Upside in IRHYTHM HLDGS (IRTC): Here's What You Should KnowMay 5 at 10:55 AM | zacks.comWhy iRhythm Holdings, Inc. (IRTC) is a Top Momentum Stock for the Long-TermMay 5 at 10:51 AM | zacks.comVanguard Group Inc. Boosts Stock Position in iRhythm Technologies $IRTCMay 5 at 8:18 AM | marketbeat.comComerica Bank Sells 13,381 Shares of iRhythm Technologies $IRTCMay 5 at 3:48 AM | marketbeat.comiRhythm Holdings, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 4 at 7:12 PM | seekingalpha.comCitigroup Issues Positive Forecast for iRhythm Technologies (NASDAQ:IRTC) Stock PriceMay 4 at 2:37 PM | marketbeat.comIRTC Stock Up on Q1 Earnings & Revenue Beat, FY26 Outlook RaisedMay 4 at 1:10 PM | zacks.comiRhythm Technologies (NASDAQ:IRTC) Given Consensus Rating of "Moderate Buy" by AnalystsMay 4 at 2:32 AM | americanbankingnews.comiRhythm Technologies (NASDAQ:IRTC) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 4 at 2:32 AM | marketbeat.comHussman Strategic Advisors Inc. Makes New Investment in iRhythm Technologies $IRTCMay 3, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC) and Apogee Therapeutics (APGE)May 3, 2026 | theglobeandmail.comAnalysts Are Bullish on Top Healthcare Stocks: Irhythm Technologies (IRTC), Pacira Pharmaceuticals (PCRX)May 3, 2026 | theglobeandmail.comNeedham & Company LLC Boosts iRhythm Technologies (NASDAQ:IRTC) Price Target to $255.00May 3, 2026 | americanbankingnews.comiRhythm Technologies (NASDAQ:IRTC) Rating Increased to Buy at Wall Street ZenMay 3, 2026 | marketbeat.comIrhythm Technologies (IRTC) Receives a Buy from Wells FargoMay 2, 2026 | theglobeandmail.comJennison Associates LLC Decreases Stake in iRhythm Technologies $IRTCMay 2, 2026 | marketbeat.comiRhythm (IRTC) Q1 2026 Earnings TranscriptMay 1, 2026 | finance.yahoo.comiRhythm posts Q1 beats, ups guidance with next-gen Zio algorithm comingMay 1, 2026 | massdevice.comiRhythm Technologies Signals Profitable Growth Amid OverhangsMay 1, 2026 | tipranks.comCanaccord Genuity Group Issues Pessimistic Forecast for iRhythm Technologies (NASDAQ:IRTC) Stock PriceMay 1, 2026 | marketbeat.comJPMorgan Chase & Co. Has Lowered Expectations for iRhythm Technologies (NASDAQ:IRTC) Stock PriceMay 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 2026Palantir Drops After Anthropic Warning—Bull Case Remains Intact By Chris Markoch | April 14, 2026Palantir Drops After a Blowout Q1—What Investors Should KnowBy Chris Markoch | May 5, 2026GMED, HAE, and IRTC Company DescriptionsGlobus Medical NYSE:GMED$86.41 -2.81 (-3.15%) As of 02:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Haemonetics NYSE:HAE$56.15 +3.48 (+6.61%) As of 02:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.iRhythm Technologies NASDAQ:IRTC$124.67 +6.97 (+5.92%) As of 02:22 PM Eastern This is a fair market value price provided by Massive. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
